Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Outperform Rating at Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report issued on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.07 EPS.

Several other equities analysts have also weighed in on the stock. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a research report on Wednesday. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 23rd. Finally, SVB Leerink started coverage on Lexicon Pharmaceuticals in a research report on Tuesday. They set an outperform rating and a $5.00 target price on the stock.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.65 on Tuesday. The stock’s 50 day moving average price is $2.13 and its 200 day moving average price is $1.74. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. The stock has a market cap of $406.30 million, a price-to-earnings ratio of -2.06 and a beta of 1.38. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. Equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. acquired a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $25,000. TIAA Trust National Association acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at $29,000. Principal Securities Inc. purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $33,000. Commonwealth Equity Services LLC increased its stake in shares of Lexicon Pharmaceuticals by 160.9% in the third quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 24,400 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 22,043 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.